

-continued

&lt;400&gt; SEQUENCE: 35

aatatggaaa gaaacgctag ggctccctgc aat

33

We claim:

1. An isolated polypeptide conjugate comprising a functional factor VIII polypeptide and one or more biocompatible polymers, wherein the functional factor VIII polypeptide comprises the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof and has a B-domain, and further wherein the biocompatible polymer comprises polyalkylene oxide and is covalently attached to the functional factor VIII polypeptide at the B-domain.
2. The isolated polypeptide conjugate of claim 1, wherein the biocompatible polymer comprises polyethylene glycol.
3. The isolated polypeptide conjugate of claim 2, wherein the polyethylene glycol comprises methoxypolyethylene glycol.
4. The isolated polypeptide conjugate of claim 3, wherein the methoxypolyethylene glycol has a size range of from 3 kD to 100 kD.
5. The isolated polypeptide conjugate of claim 3, wherein the methoxypolyethylene glycol has a size range of from 5 kD to 64 kD.
6. The isolated polypeptide conjugate of claim 3, wherein the methoxypolyethylene glycol has a size range of from 5 kD to 43 kD.
7. The isolated polypeptide conjugate of claim 2, wherein the polyethylene glycol has a size of 5, 12, 22, 30, or 43 kD.
8. A pharmaceutical composition comprising a therapeutically effective amount of the isolated polypeptide conjugate of claim 1 and a pharmaceutically acceptable adjuvant.
9. A pharmaceutical composition comprising (1) a therapeutically effective amount of a monopegylated polypeptide conjugate, wherein the monopegylated polypeptide conjugate comprises a functional factor VIII polypeptide and one polyethylene glycol polymer, the functional factor VIII polypeptide comprises the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof and has a B-domain, and the polyethylene glycol is covalently attached to the functional factor VIII polypeptide at the B-domain; and (2) a pharmaceutically acceptable adjuvant.

\* \* \* \* \*